Phospho-ELK3 (S357) Antibody

What is Phospho-ELK3 (S357) Antibody and what cellular processes does it help investigate?

Phospho-ELK3 (S357) Antibody is a specialized research tool that specifically detects ELK3 (also known as NET, SAP2) only when phosphorylated at serine 357. This antibody enables researchers to investigate ELK3's role as an ETS domain-containing transcription factor involved in critical cellular processes including cell proliferation, differentiation, migration, angiogenesis, and apoptosis .

Unlike total ELK3 antibodies, this phospho-specific antibody allows researchers to track post-translational modifications that regulate ELK3's transcriptional activity, particularly in cancer research where phosphorylation status may correlate with disease progression. The antibody is typically available as a rabbit polyclonal with reactivity to human, mouse, and monkey samples .

What are the optimal storage conditions and handling recommendations for Phospho-ELK3 (S357) Antibody?

For long-term storage, maintain Phospho-ELK3 (S357) Antibody at -20°C or -80°C to preserve its activity and specificity . The antibody is typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

For short-term usage and frequent experiments, aliquoting the antibody and storing at 4°C for up to one month is recommended to minimize freeze-thaw cycles . When handling the antibody:

• Avoid repeated freeze-thaw cycles which compromise antibody integrity

• Briefly centrifuge the vial before opening to collect all material at the bottom

• Use sterile pipette tips and tubes when making dilutions

• For phospho-specific antibodies, always use freshly prepared buffers with phosphatase inhibitors

These measures help maintain antibody performance across multiple experiments and extend its functional lifespan.

What applications is Phospho-ELK3 (S357) Antibody validated for?

Phospho-ELK3 (S357) Antibody has been validated for multiple research applications with these recommended dilutions :

The antibody has been affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen, ensuring high specificity for the phosphorylated form at Ser357 .

How should I prepare samples to maximize detection of phosphorylated ELK3?

Sample preparation is critical for phosphorylation detection. Follow these methodological steps:

• Lysis buffer composition: Use RIPA or NP-40 buffer supplemented with:

  • Phosphatase inhibitors (10 μM MG132, 1 μM MLN4924)

  • Protease inhibitors cocktail

  • 50 mM NaF, 10 mM Na₃VO₄, 10 mM β-glycerophosphate

• Sample handling:

  • Process tissues/cells rapidly on ice

  • For prostate cancer cells, harvest within 24-48 hours of treatment with relevant compounds

  • Avoid repeated freeze-thaw cycles of lysates

• Protein concentration:

  • Use 15-20 μg of total protein for Western blotting

  • For phospho-specific detection, normalize to total protein rather than housekeeping genes

  • When applying phos-tag gel electrophoresis, load 3 × 10^6 HEK293T cells to validate CHK2-mediated ELK3 phosphorylation

These techniques help preserve phosphorylation status by inhibiting endogenous phosphatases that may be activated during sample preparation.

What are the recommended protocols for detecting Phospho-ELK3 (S357) in Western blot analysis?

For optimal Western blot detection of Phospho-ELK3 (S357), follow this specific protocol:

• Sample preparation:

  • Add phosphatase inhibitors immediately before cell lysis

  • Sonicate briefly to shear DNA and reduce viscosity

• Gel electrophoresis:

  • Use freshly prepared gels (10-12% SDS-PAGE)

  • For detailed phosphorylation analysis, consider phos-tag gels to separate phosphorylated from non-phosphorylated forms

  • Expect to detect ELK3 at approximately 44 kDa

• Transfer and blocking:

  • Use PVDF membranes for phospho-protein detection

  • Block in 3% BSA in PBS (not milk, which contains phosphatases)

  • Use phospho-antibodies at 1:1000 dilution in 3% BSA in PBS

• Detection:

  • Use total ELK3 antibody (1:2000 in 5% milk/PBS) on parallel blots to compare phosphorylated vs. total protein

  • Include positive controls such as lysates from COLO cells, which show strong Phospho-ELK3 (S357) signal

This methodology allows for reliable detection of phosphorylated ELK3, enabling studies on its regulation and activity changes under various experimental conditions.

How can I validate the specificity of Phospho-ELK3 (S357) Antibody in my experimental system?

Validating antibody specificity is crucial for reliable research. Implement these methodological approaches:

• Positive and negative controls:

  • Use COLO cells as positive control for Phospho-ELK3 (S357) detection

  • Compare samples with and without treatment with phosphatase inhibitors

  • Include samples treated with lambda phosphatase as negative controls

• Specific validation experiments:

  • Implement siRNA/shRNA knockdown of ELK3 to confirm signal specificity

  • Compare with kinase inhibition: Use 5 μM AZD7762 (checkpoint kinase inhibitor) to reduce ELK3 phosphorylation

  • Pre-incubate antibody with blocking peptide derived from the immunogen sequence around Ser357 (amino acids 323-372)

• Cross-validation:

  • Compare results from multiple detection methods (WB, IHC, IF)

  • Use orthogonal methods like mass spectrometry to confirm phosphorylation sites

  • Test antibody from multiple vendors (Boster Bio, Cusabio, Qtonics) with the same samples

Proper validation ensures that experimental observations reflect true biological phenomena rather than technical artifacts.

Which kinases are responsible for ELK3 Ser357 phosphorylation and how does this affect its function?

ELK3 Ser357 phosphorylation is primarily mediated by checkpoint kinases in response to cellular stress and cell cycle regulation:

• Key kinases involved:

  • Checkpoint kinases (CHK1/CHK2) have been identified as primary mediators of ELK3 phosphorylation

  • Experimental evidence: Treatment with CHK inhibitors (AZD7762, LY2606368) at 5 μM concentration reduces ELK3 phosphorylation

  • In docetaxel treatment scenarios, checkpoint kinase activation leads to increased ELK3 phosphorylation

• Functional consequences:

  • Phosphorylation at Ser357 modulates ELK3's transcriptional activity

  • Phosphorylated ELK3 shows increased interaction with SPOP, leading to ubiquitination and subsequent degradation

  • This degradation pathway impacts downstream target gene expression, including c-Fos-regulated genes involved in cell proliferation and invasion

• Regulation dynamics:

  • ELK3 phosphorylation changes during cell cycle progression, with decreased levels during S-M phase

  • Phosphorylation status correlates with proteasomal degradation pathways, linking post-translational modification to protein stability

Understanding these phosphorylation mechanisms provides insight into how ELK3 activity is regulated in both normal cellular processes and disease states.

What is the relationship between ELK3 phosphorylation, SPOP interaction, and protein degradation?

The relationship between ELK3 phosphorylation, SPOP interaction, and protein degradation represents a critical regulatory mechanism:

• Phosphorylation-dependent recognition:

  • Checkpoint kinase-mediated phosphorylation of ELK3 at Ser357 creates a recognition site for SPOP binding

  • This phosphorylation is a prerequisite for efficient SPOP-ELK3 interaction

• SPOP-mediated ubiquitination mechanism:

  • SPOP (speckle-type POZ protein) functions as a substrate recognition component of the cullin3-based ubiquitin E3 ligase complex

  • The interaction between SPOP and phosphorylated ELK3 results in increased ELK3 ubiquitination

  • Experimental evidence: Treatment with proteasome inhibitor MG132 (10 μM) prevents degradation of phosphorylated ELK3

• Biological significance:

  • This degradation pathway regulates ELK3 protein levels, controlling its transcriptional activity

  • In prostate cancer, SPOP mutations disrupt this degradation pathway, leading to ELK3 stabilization

  • Immunohistochemical analysis of 123 prostate cancer tissues revealed an inverse correlation between SPOP and ELK3 expression in ~80% of specimens

This molecular pathway provides a mechanistic understanding of how post-translational modifications control ELK3 protein stability and function in normal and disease states.

How does ELK3 phosphorylation status influence prostate cancer progression and treatment response?

ELK3 phosphorylation status has emerged as a critical factor in prostate cancer biology with significant implications for disease progression and treatment:

• Role in cancer progression:

  • ELK3 promotes prostate cancer cell proliferation, migration, and invasion

  • Silencing of ELK3 induces S-M phase arrest and promotes apoptosis in prostate cancer cells

  • Knockdown experiments show decreased expression of cyclin A and cyclin B, consistent with cell cycle arrest

• Treatment response mechanisms:

  • Docetaxel treatment activates checkpoint kinases, leading to ELK3 phosphorylation and subsequent SPOP-mediated degradation

  • SPOP-depleted or SPOP-mutated prostate cancer cells exhibit docetaxel resistance, correlating with stabilized ELK3 levels

  • Experimental evidence: SPOP mutations were found to contribute directly to docetaxel resistance in prostate cancer models

• Clinical correlations:

  • Immunohistochemical analysis of 123 prostate cancer tissues revealed an inverse correlation between SPOP and ELK3 expression in ~80% of specimens

  • ELK3 levels correlate with worse outcomes in patients receiving docetaxel-based therapy when SPOP mutations are present

These findings highlight how the phosphorylation-dependent regulation of ELK3 represents both a biomarker for treatment response and a potential therapeutic target in prostate cancer.

How can targeting ELK3 phosphorylation potentially impact cancer therapeutic approaches?

Targeting ELK3 phosphorylation offers several promising therapeutic strategies:

• Direct modulation of phosphorylation:

  • Enhancing ELK3 phosphorylation could accelerate its degradation in cancers with intact SPOP

  • Kinase activators specifically targeting checkpoint kinases could increase ELK3 phosphorylation at Ser357

  • In experimental models, compounds like AZD7762 (5 μM) affected ELK3 phosphorylation levels

• Combination therapies:

  • For docetaxel-resistant prostate cancers with SPOP mutations, targeting downstream ELK3 pathways could restore sensitivity

  • Experimental evidence suggests that inhibiting ELK3 function could overcome treatment resistance mechanisms

  • Stratifying patients based on SPOP mutation status and ELK3 expression could personalize treatment approaches

• Novel degradation pathways:

  • Developing proteolysis-targeting chimeras (PROTACs) specific for ELK3 could bypass the need for SPOP

  • These approaches could be particularly valuable in SPOP-mutant tumors where natural degradation pathways are compromised

  • Transcriptional measurements using real-time PCR (as in Hela cells stably expressing sh-mock or sh-SPOP) could help identify effective degradation strategies

These therapeutic approaches highlight how understanding the molecular mechanisms of ELK3 phosphorylation and degradation provides opportunities for targeted cancer interventions.

What methods are available for quantitative analysis of ELK3 phosphorylation dynamics?

For quantitative analysis of ELK3 phosphorylation dynamics, researchers can employ several sophisticated methodologies:

• Phospho-specific assays:

  • Transcription factor activity assays specifically designed for Phospho-ELK3 (S357) offer high sensitivity and specificity for detecting active ELK3

  • These assays can detect Phospho-ELK3 (S357) in nuclear or cell lysates from human, mouse, and rat samples

  • Colorimetric detection at 450 nm allows for quantitative measurement of phosphorylation levels

• Advanced gel-based techniques:

  • Phos-tag gel electrophoresis can separate phosphorylated from non-phosphorylated forms of ELK3

  • This technique allows visualization of multiple phosphorylation states simultaneously

  • Western blotting following phos-tag separation provides semi-quantitative analysis of phosphorylation ratios

• Live-cell imaging approaches:

  • Combining phospho-specific antibodies with proximity ligation assays can visualize ELK3 phosphorylation in situ

  • FRET-based biosensors designed around the Ser357 region could enable real-time monitoring of phosphorylation events

  • Flow cytometry using phospho-specific antibodies (similar to techniques used for STAT4 phosphorylation analysis) can quantify cellular distributions

These advanced methods enable researchers to move beyond static measurements to understand the dynamic regulation of ELK3 phosphorylation in cellular processes and disease states.

How can I integrate Phospho-ELK3 (S357) data with other molecular and cellular findings?

Integrating Phospho-ELK3 (S357) data with other molecular and cellular findings requires multidisciplinary approaches:

• Multi-omics integration strategies:

  • Correlate Phospho-ELK3 (S357) levels with transcriptomic data of ELK3 target genes

  • Perform ChIP-seq following phosphorylation analysis to identify differential binding sites of phosphorylated versus non-phosphorylated ELK3

  • Integrate with proteomic data to identify protein interaction networks influenced by ELK3 phosphorylation status

• Pathway analysis approaches:

  • Consider relationships with other ETS family transcription factors

  • Map connections to checkpoint kinase pathways and SPOP-mediated degradation mechanisms

  • Create computational models similar to the kinetic computational models used for protein-protein interactions described for receptor antibodies

• Functional validation methods:

  • Develop phosphomimetic (S357D/E) and phospho-dead (S357A) ELK3 mutants to study functional consequences

  • Perform rescue experiments in ELK3 knockdown cells with these mutants

  • Correlate with phenotypic outcomes including cell cycle arrest (S-M phase), apoptosis, and migration parameters documented in prostate cancer studies

This integrative approach allows researchers to build comprehensive models of how ELK3 phosphorylation fits within broader cellular networks and signaling pathways.

What are common pitfalls when detecting Phospho-ELK3 (S357) in clinical samples?

Detecting Phospho-ELK3 (S357) in clinical samples presents several challenges that require specific methodological solutions:

• Sample preservation issues:

  • Phosphorylation can be rapidly lost during sample collection and processing

  • Solution: Immediate fixation or flash-freezing of samples; use of phosphatase inhibitors during all processing steps

  • For immunohistochemistry, optimized fixation protocols using phosphorylation-preserving fixatives are essential

• Signal specificity challenges:

  • Cross-reactivity with other phosphorylated ETS family members

  • Solution: Always include blocking peptide controls specific to the Ser357 region (amino acids 323-372)

  • Use multiple antibodies from different vendors (Boster Bio, Cusabio, antibodies.com) to validate findings

• Quantitative limitations:

  • Variable phosphorylation levels between patient samples

  • Solution: Normalize to total ELK3 expression; use Phospho-ELK3 (S357) to total ELK3 ratio

  • Include phosphorylation-resistant controls (S357A mutants) when possible

  • For IHC applications, use dilutions of 1:100-1:300 and standardized scoring systems

Addressing these challenges enables more reliable detection of Phospho-ELK3 (S357) in clinical samples, improving the translational relevance of research findings.

How can I optimize immunohistochemistry protocols for Phospho-ELK3 (S357) detection in tissue sections?

Optimizing immunohistochemistry protocols for Phospho-ELK3 (S357) requires special considerations:

• Tissue preparation and fixation:

  • Fixation time is critical: overfixation can mask phospho-epitopes

  • Recommended protocol: 10% neutral buffered formalin for 24 hours maximum

  • Phosphatase inhibitors can be included in fixatives to preserve phosphorylation status

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) works well for many phospho-epitopes

  • Test multiple antigen retrieval methods (citrate, EDTA, enzymatic) to determine optimal conditions

  • For Phospho-ELK3 (S357), a prolonged retrieval (20 minutes) often improves signal detection

• Antibody incubation parameters:

  • Use recommended dilutions of 1:100-1:300 for IHC applications

  • Overnight incubation at 4°C often yields better results than shorter incubations

  • Include blocking steps with 1% BSA and 5% normal serum from the same species as the secondary antibody

• Signal development and validation:

  • Use amplification systems (polymer-based detection) for enhanced sensitivity

  • Include positive controls (prostate cancer tissue samples with known ELK3 expression)

  • Validate with parallel staining using total ELK3 antibody on consecutive sections